Tokyo: Eisai Co., Ltd. and Biogen Inc. have announced that the U.S. Food and Drug Administration (FDA) has approved the ...

Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatmentAlzheimer's disease progression does ...

BioArctic AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once ...

Jupiter is actively exploring additional strategic partnerships to expand JOTROL’s application across other neuroinflammatory and metabolic disorders, including Alzheimer’s disease and longevity ...

Summary: Delayed rapid eye movement (REM) sleep may be an early indicator of Alzheimer’s disease. Researchers found that participants with delayed REM sleep had higher levels of toxic proteins ...

Jupiter Neurosciences, Inc. (NASDAQ: JUNS) ("Jupiter" or the "Company"), a clinical-stage pharmaceutical company developing JOTROL, a patented resveratrol-based ...

New research reveals that maintaining an active social life in later years could significantly delay the onset of dementia and mild cognitive impairment (MCI). The study, published in Alzheimer's & ...

In simulated trial, FDI achieved mean absolute errors of 1.57 and 0.70 years for predicting MCI, AD onset, respectively.

Triple semicircular canal plugging (TSCP) is effective for vertigo control but is associated with a risk for hearing loss in ...

A discovery about the mechanisms that enable the immune system to sustain long-term protection could revolutionize treatment for chronic disease and cancer.

After hours: January 31 at 6:27:43 PM EST Loading Chart for MCI ...